Top

Published in:

01-02-2020 | Review

Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review

Authors: Josephine R. Coury, Brittany N. Davis, Christoforos P. Koumas, Giovanna S. Manzano, Amir R. Dehdashti

Published in: Neurosurgical Review | Issue 1/2020

Abstract

Craniopharyngiomas (CPs) are rare, benign tumors derived from Rathke’s pouch, known for their high recurrence rates and associated morbidity and mortality. Despite significant investigation on risk factors for recurrence, a lack of consensus persists. Recent research suggests that specific histopathological and molecular characteristics are prognostic for disease progression. In this systematic review, we analyzed and consolidated key features of CPs that contribute to increased recurrence rates. This systematic review was performed in accordance with PRISMA guidelines. A search string was created with the keywords “craniopharyngioma,” “histology,” “histopathology,” “molecular,” and “recurrence.” Literature was collected from 2006 to 2016 on the PubMed/Medline and Web of Science databases. The initial search resulted in 242 papers, examined with inclusion and exclusion criteria. The final review included a total of 37 studies, 36 primary studies covering a total of 1461 patients and 1 previous meta-analysis. Cystic lesions and whorl-like arrays were found to be associated with increased recurrence, while previously considered reactive gliosis and finger-shaped protrusions were not. The genetic elements found to be associated with increased risk of recurrence were Ki-67, Ep-CAM, PTTG-1, survivin, and certain RAR isotypes, as well as the glycoproteins osteonectin and chemokines CXCL12/CXCR4. The effects of VEGF, HIF-1α, and p53, despite extensive study, yielded conflicting results. Certain histopathological and molecular characteristics of CPs provide insight into their pathogenesis, likelihood of recurrence, and potential novel targets for therapy.

Agozzino L, Ferraraccio F, Accardo M, Esposito S, Agozzino M, Cuccurullo L (2006) Morphological and ultrastructural findings of prognostic impact in craniopharyngiomas. Ultrastruct Pathol 30:143–150. https://doi.org/10.1080/01913120500408018 CrossRefPubMed

Anegawa S, Hayashi T, Nakagawa S, Furukawa Y, Tomokiyo M (2001) Craniopharyngioma with rapid regrowth—role of MIB-1 labeling index. No Shinkei Geka 29:727–733PubMed

Bao Y, Peng JX (2016) Origin of craniopharyngiomas: implications for growth pattern, clinical characteristics, and outcomes of tumor recurrence. J Clin Neurosci 125:24–32. https://doi.org/10.3171/2015.6.JNS141883 CrossRef

Bao Y, Qiu BH, Qi ST, Pan J, Lu YT, Peng JX (2016) Influence of previous treatments on repeat surgery for recurrent craniopharyngiomas in children. Childs Nerv Syst 32:485–491. https://doi.org/10.1007/s00381-015-3003-0 CrossRefPubMed

Bartlett JR (1971) Craniopharyngiomas. An analysis of some aspects of symptomatology, radiology and histology. Brain J Neurol 94:725–732. https://doi.org/10.1093/brain/94.4.725 CrossRef

Botti G, Scognamiglio G, Marra L, Collina F, Di Bonito M, Cerrone M, Grilli B, Anniciello A, Franco R, Fulciniti F, Ascierto PA, Cantile M (2014) SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression. Virchows Arch 465:331–338. https://doi.org/10.1007/s00428-014-1616-4 CrossRefPubMed

Brastianos PK, Santagata S (2016) BRAF V600E mutations in papillary craniopharyngioma. Eur J Endocrinol 174:R139–R144CrossRef

Brastianos PK, Taylor-Weiner A, Manley PE, Jones RT, Dias-Santagata D, Thorner AR, Lawrence MS, Rodriguez FJ, Bernardo LA, Schubert L, Sunkavalli A, Shillingford N, Calicchio ML, Lidov HGW, Taha H, Martinez-Lage M, Santi M, Storm PB, Lee JYK, Palmer JN, Adappa ND, Scott RM, Dunn IF, Laws ER, Stewart C, Ligon KL, Hoang MP, Van Hummelen P, Hahn WC, Louis DN, Resnick AC, Kieran MW, Getz G, Santagata S (2014) Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 46:161–U100. https://doi.org/10.1038/ng.2868 CrossRefPubMedPubMedCentral

Brastianos PK, Shankar GM, Gill CM, Taylor-Weiner A, Nayyar N, Panka DJ, Sullivan RJ, Frederick DT, Abedalthagafi M, Jones PS, Dunn IF, Nahed BV, Romero JM, Louis DN, Getz G, Cahill DP, Santagata S, Curry WT, Barker FG (2016) Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. JNCI-J Natl Cancer Inst 108:5. https://doi.org/10.1093/jnci/djv310 CrossRef

10.

Burghaus S, Holsken A, Buchfelder M, Fahlbusch R, Riederer BM, Hans V, Blumcke I, Buslei R (2010) A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas. Virchows Arch 456:287–300. https://doi.org/10.1007/s00428-009-0873-0 CrossRefPubMed

11.

Buslei R, Nolde M, Hofmann B, Meissner S, Eyupoglu IY, Siebzehnrubl F, Hahnen E, Kreutzer J, Fahlbusch R (2005) Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol 109:589–597. https://doi.org/10.1007/s00401-005-1004-x CrossRefPubMed

12.

Cao J, Lin JP, Yang LX, Chen K, Huang ZS (2010) Expression of aberrant beta-catenin and impaired p63 in craniopharyngiomas. Br J Neurosurg 24:249–256. https://doi.org/10.3109/02688690903576237 CrossRefPubMed

13.

Cavallo LM, Frank G, Cappabianca P, Solari D, Mazzatenta D, Villa A, Zoli M, D'Enza AI, Esposito F, Pasquini E (2014) The endoscopic endonasal approach for the management of craniopharyngiomas: a series of 103 patients. J Neurosurg 121:100–113. https://doi.org/10.3171/2014.3.jns131521 CrossRefPubMed

14.

Cermak S, Kosicek M, Mladenovic-Djordjevic A, Smiljanic K, Kanazir S, Hecimovic S (2016) Loss of cathepsin B and L leads to lysosomal dysfunction, NPC-like cholesterol sequestration and accumulation of the key Alzheimer’s proteins. PLoS One 11:17. https://doi.org/10.1371/journal.pone.0167428 CrossRef

15.

Chuwa AH, Sone K, Oda K, Ikeda Y, Fukuda T, Wada-Hiraike O, Inaba K, Makii C, Takeuchi M, Oki S, Miyasaka A, Kashiyama T, Arimoto T, Kuramoto H, Kawana K, Yano T, Osuga Y, Fujii T (2016) Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer. Gynecol Oncol 141:564–569. https://doi.org/10.1016/j.ygyno.2016.04.003 CrossRefPubMed

16.

Crotty TB, Scheithauer BW, Young WF, Davis DH, Shaw EG, Miller GM, Burger PC (1995) Papillary craniopharyngioma—a clinicopathological study of 48 cases. J Neurosurg 83:206–214. https://doi.org/10.3171/jns.1995.83.2.0206 CrossRefPubMed

17.

Cseh B, Doma E, Baccarini M (2014) “RAF” neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway. FEBS Lett 588:2398–2406. https://doi.org/10.1016/j.febslet.2014.06.025 CrossRefPubMedPubMedCentral

18.

Dehdashti AR, Ganna A, Witterick I, Gentili F (2009) Expanded endoscopic endonasal approach for anterior cranial base and suprasellar lesions: indications and limitations. Neurosurgery 64:677–687; discussion 687-679. https://doi.org/10.1227/01.neu.0000339121.20101.85 CrossRefPubMed

19.

Drimtzias E, Falzon K, Picton S, Jeeva I, Guy D, Nelson O, Simmons I (2014) The ophthalmic natural history of paediatric craniopharyngioma: a long-term review. J Neuro-Oncol 120:651–656. https://doi.org/10.1007/s11060-014-1600-5 CrossRef

20.

Duff JM, Meyer FB, Ilstrup DM, Laws ER, Schleck CD, Scheithauer BW (2000) Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery 46:291–302. https://doi.org/10.1097/00006123-200002000-00007 CrossRefPubMed

21.

Duo D, Gasverde S, Benech F, Zenga F, Giordana MT (2003) MIB-1 immunoreactivity in craniopharyngiomas: a clinico-pathological analysis. Clin Neuropathol 22:229–234PubMed

22.

Ebrahimi A, Honegger J, Schluesener H, Schittenhelm J (2013) Osteonectin expression in surrounding stroma of craniopharyngiomas: association with recurrence rate and brain infiltration. Int J Surg Pathol 21:591–598. https://doi.org/10.1177/1066896913486695 CrossRefPubMed

23.

Garnett MR, Puget S, Grill J, Sainte-Rose C (2007) Craniopharyngioma. Orphanet J Rare Dis 2:18. https://doi.org/10.1186/1750-1172-2-18 CrossRefPubMedPubMedCentral

24.

Gong J, Zhang HL, Xing SS, Li CD, Ma ZY, Jia G, Hu WN (2014) High expression levels of CXCL12 and CXCR4 predict recurrence of adamantinomatous craniopharyngiomas in children. Cancer Biomark 14:241–251. https://doi.org/10.3233/cbm-140397 CrossRefPubMed

25.

Gupta DK, Ojha BK, Sarkar C, Mahapatra AK, Mehta VS (2006) Recurrence in craniopharyngiomas: analysis of clinical and histological features. J Clin Neurosci 13:438–442. https://doi.org/10.1016/j.jocn.2005.05.013 CrossRefPubMed

26.

Gupta DK, Ojha BK, Sarkar C, Mahapatra AK, Sharma BS, Mehta VS (2006) Recurrence in pediatric craniopharyngiomas: analysis of clinical and histological features. Childs Nerv Syst 22:50–55. https://doi.org/10.1007/s00381-005-1171-z CrossRefPubMed

27.

Holsken A, Stache C, Schlaffer SM, Flitsch J, Fahlbusch R, Buchfelder M, Buslei R (2014) Adamantinomatous craniopharyngiomas express tumor stem cell markers in cells with activated Wnt signaling: further evidence for the existence of a tumor stem cell niche? Pituitary 17:546–556. https://doi.org/10.1007/s11102-013-0543-8 CrossRefPubMed

28.

Hussain I, Eloy JA, Carmel PW, Liu JK (2013) Molecular oncogenesis of craniopharyngioma: current and future strategies for the development of targeted therapies A review. J Neurosurg 119:106–112. https://doi.org/10.3171/2013.3.jns122214 CrossRefPubMed

29.

Ishida M, Hotta M, Tsukamura A, Taga T, Kato H, Ohta S, Takeuchi Y, Nakasu S, Okabe H (2010) Malignant transformation in craniopharyngioma after radiation therapy: a case report and review of the literature. Clin Neuropathol 29:2–8CrossRef

30.

Izumoto S, Suzuki T, Kinoshita M, Hashiba T, Kagawa N, Wada K, Fujimoto Y, Hashimoto N, Saitoh Y, Maruno M, Yoshimine T (2005) Immunohistochemical detection of female sex hormone receptors in craniopharyngiomas: correlation with clinical and histologic features. Surg Neurol 63:520–525. https://doi.org/10.1016/j.surneu.2004.08.094 CrossRefPubMed

31.

Kapinas K, Lowther KM, Kessler CB, Tilbury K, Lieberman JR, Tirnauer JS, Campagnola P, Delany AM (2012) Bone matrix osteonectin limits prostate cancer cell growth and survival. Matrix Biol 31:299–307. https://doi.org/10.1016/j.matbio.2012.03.002 CrossRefPubMedPubMedCentral

32.

Kato K, Nakatani Y, Kanno H, Inayama Y, Ijiri R, Nagahara N, Miyake T, Tanaka M, Ito Y, Aida N, Tachibana K, Sekido K, Tanaka Y (2004) Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma. J Pathol 203:814–821. https://doi.org/10.1002/path.1562 CrossRefPubMed

33.

Katz EL (1975) Late results of radical excision of craniopharyngiomas in children. J Neurosurg 42:86–93. https://doi.org/10.3171/jns.1975.42.1.0086 CrossRefPubMed

34.

Kim S, An SS (2016) Role of p53 isoforms and aggregations in cancer. Medicine 95:e3993. https://doi.org/10.1097/md.0000000000003993 CrossRefPubMedPubMedCentral

35.

Kim SK, Wang KC, Shin SH, Choe G, Chi JG, Cho BK (2001) Radical excision of pediatric craniopharyngioma: recurrence pattern and prognostic factors. Childs Nerv Syst 17:531–536. https://doi.org/10.1007/s003810100458 CrossRefPubMed

36.

Kobayashi T, Tsugawa T, Hatano M, Hashizume C, Mori Y, Shibamoto Y (2015) Gamma knife radiosurgery of craniopharyngioma: results of 30 cases treated at Nagoya Radiosurgery Center. Nagoya J Med Sci 77:447–454PubMedPubMedCentral

37.

Koutourousiou M, Gardner PA, Fernandez-Miranda JC, Tyler-Kabara EC, Wang EW, Snyderman CH (2013) Endoscopic endonasal surgery for craniopharyngiomas: surgical outcome in 64 patients Clinical article. J Neurosurg 119:1194–1207. https://doi.org/10.3171/2013.6.jns122259 CrossRefPubMed

38.

Larkin SJ, Ansorge O (2013) Pathology and pathogenesis of craniopharyngiomas. Pituitary 16:9–17. https://doi.org/10.1007/s11102-012-0418-4 CrossRefPubMed

39.

Lee EJ, Cho YH, Hong SH, Kim JH, Kim CJ (2015) Is the complete resection of craniopharyngiomas in adults feasible considering both the oncologic and functional outcomes? J Korean Neurosurg Soc 58:432–441. https://doi.org/10.3340/jkns.2015.58.5.432 CrossRefPubMedPubMedCentral

40.

Lefranc F, Chevalier C, Vinchon M, Dhellemmes P, Schuring MP, Kaltner H, Brotchi J, Ruchoux MM, Gabius HJ, Salmon I, Kiss R (2003) Characterization of the levels of expression of retinoic acid receptors, galectin-3, macrophage migration inhibiting factor, and p53 in 51 adamantinomatous craniopharyngiomas. J Neurosurg 98:145–153. https://doi.org/10.3171/jns.2003.98.1.0145 CrossRefPubMed

41.

Lefranc F, Mijatovic T, Decaestecker C, Kaltner H, Andre S, Brotchi J, Salmon I, Gabius HJ, Kiss R (2005) Monitoring the expression profiles of integrins and adhesion/growth-regulatory galectins in adamantinomatous craniopharyngiomas: their ability to regulate tumor adhesiveness to surrounding tissue and their contribution to prognosis. Neurosurgery 56:763–776CrossRef

42.

Liu H, Liu ZY, Li J, Li Q, You C, Xu JG (2014) Relative quantitative expression of hypoxia-inducible factor 1 alpha messenger ribonucleic acid in recurrent craniopharyngiomas. Neurol India 62:53–56. https://doi.org/10.4103/0028-3886.128291 CrossRefPubMed

43.

Liubinas SV, Munshey AS, Kaye AH (2011) Management of recurrent craniopharyngioma. J Clin Neurosci 18:451–457. https://doi.org/10.1016/j.jocn.2010.10.004 CrossRefPubMed

44.

Losa M, Vimercati A, Acerno S, Barzaghi RL, Mortini P, Mangili F, Terreni MR, Santambrogio G, Giovanelli M (2004) Correlation between clinical characteristics and proliferative activity in patients with craniopharyngioma. J Neurol Neurosurg Psychiatry 75:889–892CrossRef

45.

Lubansu A, Ruchoux MM, Brotchi J, Salmon I, Kiss R, Lefranc F (2003) Cathepsin B, D and K expression in adamantinomatous craniopharyngiomas relates to their levels of differentiation as determined by the patterns of retinoic acid receptor expression. Histopathology 43:563–572. https://doi.org/10.1111/j.1365-2559.2003.01751.x CrossRefPubMed

46.

Metzger J, Nachanakian A, Gardeur D, Sichez JP (1979) CT follow-up studies in postoperative craniopharyngiomas. Acta Neurochir Suppl 28:357–361PubMed

47.

Minamida Y, Mikami T, Hashi K, Houkin K (2005) Surgical management of the recurrence and regrowth of craniopharyngiomas. J Neurosurg 103:224–232. https://doi.org/10.3171/jns.2005.103.2.0224 CrossRefPubMed

48.

Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang LQ, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu SX (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613–2622. https://doi.org/10.1038/sj/onc/1205353 CrossRefPubMed

49.

Momota H, Ichimiya S, Ikeda T, Yamaki T, Kikuchi T, Houkin K, Sato N (2003) Immunohistochemical analysis of the p53 family members in human craniopharyngiomas. Brain Tumor Pathol 20:73–77. https://doi.org/10.1007/bf02483450 CrossRefPubMed

50.

Mortini P, Gagliardi F, Boari N, Losa M (2013) Surgical strategies and modern therapeutic options in the treatment of craniopharyngiomas. Crit Rev Oncol/Hematol 88:514–529. https://doi.org/10.1016/j.critrevonc.2013.07.013 CrossRef

51.

Muller HL (2014) Craniopharyngioma. Endocr Rev 35:513–543. https://doi.org/10.1210/er.2013-1115 CrossRefPubMed

52.

Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O (2004) The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23:5748–5758. https://doi.org/10.1038/sj.onc.1207610 CrossRefPubMed

53.

Nishi T, Kuratsu J, Takeshima H, Saito Y, Kochi M, Ushio Y (1999) Prognostic significance of the MIB-1 labeling index for patient with craniopharyngioma. Int J Mol Med 3:157–161PubMed

54.

Papatheodorou H, Papanastasiou AD, Sirinian C, Scopa C, Kalofonos HP, Leotsinidis M, Papadaki H (2014) Expression patterns of SDF1/CXCR4 in human invasive breast carcinoma and adjacent normal stroma: correlation with tumor clinicopathological parameters and patient survival. Pathol Res Pract 210:662–667. https://doi.org/10.1016/j.prp.2014.06.015 CrossRefPubMed

55.

Pekmezci M, Louie J, Gupta N, Bloomer MM, Tihan T (2010) Clinicopathological characteristics of adamantinomatous and papillary craniopharyngiomas: University of California, San Francisco experience 1985–2005. Neurosurgery 67:1341–1349. https://doi.org/10.1227/NEU.0b013e3181f2b583 CrossRefPubMed

56.

Prieto R, Pascual JM, Subhi-Issa I, Jorquera M, Yus M, Martinez R (2013) Predictive factors for craniopharyngioma recurrence: a systematic review and illustrative case report of a rapid recurrence. World Neurosurg 79:733–749. https://doi.org/10.1016/j.wneu.2012.07.033 CrossRefPubMed

57.

Qi ST, Lu YT, Pan J, Zhang XA, Long H, Fan J (2011) Anatomic relations of the arachnoidea around the pituitary stalk: relevance for surgical removal of craniopharyngiomas. Acta Neurochir 153:785–796. https://doi.org/10.1007/s00701-010-0940-y CrossRefPubMed

58.

Raghavan R, Dickey WT Jr, Margraf LR, White Iii CL, Coimbra C, Hynan LS, Rushing EJ (2000) Proliferative activity in craniopharyngiomas: clinicopathological correlations in adults and children. Surg Neurol 54:241–248. https://doi.org/10.1016/S0090-3019(00)00298-6 CrossRefPubMed

59.

Rodriguez FJ, Scheithauer BW, Tsunoda S, Kovacs K, Vidal S, Piepgras DG (2007) The spectrum of malignancy in craniopharyngioma. Am J Surg Pathol 31:1020–1028. https://doi.org/10.1097/PAS.0b013e31802d8a96 CrossRefPubMed

60.

Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322. https://doi.org/10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9 CrossRefPubMed

61.

Schweizer L, Capper D, Holsken A, Fahlbusch R, Flitsch J, Buchfelder M, Herold-Mende C, von Deimling A, Buslei R (2015) BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke’s cleft cysts. Neuropathol Appl Neurobiol 41:733–742. https://doi.org/10.1111/nan.12201 CrossRefPubMed

62.

Sekine S, Shibata T, Kokubu A, Morishita Y, Noguchi M, Nakanishi Y, Sakamoto M, Hirohashi S (2002) Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol 161:1997–2001CrossRef

63.

Stache C, Holsken A, Schlaffer SM, Hess A, Metzler M, Frey B, Fahlbusch R, Flitsch J, Buchfelder M, Buslei R (2015) Insights into the infiltrative behavior of adamantinomatous craniopharyngioma in a new xenotransplant mouse model. Brain Pathol 25:1–10. https://doi.org/10.1111/bpa.12148 CrossRefPubMed

64.

Steno J, Bizik I, Steno A, Matejcik V (2014) Recurrent craniopharyngiomas in children and adults: long-term recurrence rate and management. Acta Neurochir 156:113–122. https://doi.org/10.1007/s00701-013-1938-z CrossRefPubMed

65.

Sun J, Nemoto E, Hong G, Sasaki K (2016) Modulation of stromal cell-derived factor 1 alpha (SDF-1alpha) and its receptor CXCR4 in Porphyromonas gingivalis-induced periodontal inflammation. BMC Oral Health 17:26. https://doi.org/10.1186/s12903-016-0250-8 CrossRefPubMedPubMedCentral

66.

Szeifert GT, Sipos L, Horvath M, Sarker MH, Major O, Salomvary B, Czirjak S, Balint K, Slowik F, Kolonics L, Pasztor E (1993) Pathological characteristics of surgically removed craniopharyngiomas—analysis of 131 cases. Acta Neurochir 124:139–143. https://doi.org/10.1007/bf01401137 CrossRefPubMed

67.

Tavangar SM, Larijani B, Mahta A, Hosseini SM, Mehrazine M, Bandarian F (2004) Craniopharyngioma: a clinicopathological study of 141 cases. Endocr Pathol 15:339–344CrossRef

68.

Tena-Suck ML, Salinas-Lara C, Arce-Arellano RI, Rembao-Bojorquez D, Morales-Espinosa D, Sotelo J, Arrieta O (2006) Clinico-pathological and immunohistochemical characteristics associated to recurrence/regrowth of craniopharyngiomas. Clin Neurol Neurosurg 108:661–669. https://doi.org/10.1016/j.clineuro.2006.01.007 CrossRefPubMed

69.

Tena-Suck ML, Ortiz-Plata A, Galan F, Sanchez A (2009) Expression of epithelial cell adhesion molecule and pituitary tumor transforming gene in adamantinomatous craniopharyngioma and its correlation with recurrence of the tumor. Ann Diagn Pathol 13:82–88. https://doi.org/10.1016/j.anndiagpath.2008.12.004 CrossRefPubMed

70.

Thimsen V, Holsken A, Buchfelder M, Flitsch J, Fahlbusch R, Stefanits H, Losa M, Jones DTW, Buslei R (2016) EpCAM (CD326) is differentially expressed in craniopharyngioma subtypes and Rathke’s cleft cysts. Sci Rep 6:10. https://doi.org/10.1038/srep29731 CrossRef

71.

Ujifuku K, Matsuo T, Takeshita T, Hayashi Y, Hayashi K, Kitagawa N, Hayashi T, Suyama K, Nagata I (2010) Malignant transformation of craniopharyngioma associated with moyamoya syndrome—case report. Neurol Med-Chir 50:599–603CrossRef

72.

Weiner HL, Wisoff JH, Rosenberg ME, Kupersmith MJ, Cohen H, Zagzag D, Shiminskimaher T, Flamm ES, Epstein FJ, Miller DC (1994) Craniopharyngiomas—a clinicopathological analysis of factors predictive of recurrence and functional. Neurosurgery 35:1001–1010CrossRef

73.

Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94:128–135. https://doi.org/10.1038/sj.bjc.6602924 CrossRefPubMedPubMedCentral

74.

Xu JG, Zhang SH, You C, Wang XJ, Zhou Q (2006) Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma. Surg Neurol 66:30–34. https://doi.org/10.1016/j.surneu.2006.05.047 CrossRef

75.

Yalcin N, Akbulut M, Cagli S, Bir F, Demirtas E (2009) Prognostic significance of the Ki-67 labeling index and P53 protein expression for patient with craniopharyngioma. J Neurol Sci-Turk 26:286–291

76.

Yosef L, Ekkehard KM, Shalom M (2016) Giant craniopharyngiomas in children: short- and long-term implications. Childs Nerv Syst 32:79–88. https://doi.org/10.1007/s00381-015-2961-6 CrossRefPubMed

77.

Yu R, Melmed S (2001) Oncogene activation in pituitary tumors. Brain Pathol 11:328–341CrossRef

78.

Zhu J, You C (2015) Craniopharyngioma: survivin expression and ultrastructure. Oncol Lett 9:75–80. https://doi.org/10.3892/ol.2014.2690 CrossRefPubMed

79.

Zygourakis CC, Kaur G, Kunwar S, McDermott MW, Madden M, Oh T, Parsa AT (2014) Modern treatment of 84 newly diagnosed craniopharyngiomas. J Clin Neurosci 21:1558–1566. https://doi.org/10.1016/j.jocn.2014.03.005 CrossRefPubMed

Title: Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review
Authors: Josephine R. Coury
Brittany N. Davis
Christoforos P. Koumas
Giovanna S. Manzano
Amir R. Dehdashti
Publication date: 01-02-2020
Publisher: Springer Berlin Heidelberg
Published in: Neurosurgical Review / Issue 1/2020
Print ISSN: 0344-5607
Electronic ISSN: 1437-2320
DOI: https://doi.org/10.1007/s10143-018-0978-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Prevalence of concomitant traumatic cranio-spinal injury: a systematic review and meta-analysis

Modern radiosurgical and endovascular classification schemes for brain arteriovenous malformations

Inferolateral thalamic ischemia secondary to PCA P2 perforator occlusion mimics MCA stroke syndrome

The application of nasoseptal “rescue” flap technique in endoscopic transsphenoidal pituitary adenoma resection

Long-term follow-up after surgical removal of meningioma of the inner third of the sphenoidal wing: outcome determinants and different strategies

Impact of robot-assisted spine surgery on health care quality and neurosurgical economics: A systemic review